VGT 309
Alternative Names: VGT-309; VGT309 - Vergent BioscienceLatest Information Update: 01 Feb 2024
At a glance
- Originator Vergent Bioscience
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II Lung cancer
Most Recent Events
- 28 Jan 2024 Updated efficacy and adverse events data from the phase II trial in Lung cancer released by Vergent Bioscience
- 05 Oct 2023 Vergent Biosciences initiates a phase II VISUALIZE trial in Lung cancer (Diagnosis) in USA (IV) (NCT06145048)
- 13 Sep 2023 Stanford University plans an early phase I trial for Colorectal cancer (IV, Infusion) in USA, in September 2023 (NCT06034197) (IRB-68096)